Article

Farnesol, a Potential Efflux Pump Inhibitor in Mycobacterium smegmatis

Jing Jin 1,†, Ji-Yu Zhang 2,†, Na Guo 3,†, Hui Sheng 4, Lei Li 1, Jun-Chao Liang 1, Xue-Lin Wang 1, Yang Li 1, Ming-Yuan Liu 1, Xiu-Ping Wu 1,* and Lu Yu 1,*

1 Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, 130062, China
2 Key and Open Laboratory of Veterinary Pharmaceutical Engineering, Lanzhou Institute of Animal Science and Veterinary Pharmaceutics, Chinese Academy of Agricultural Sciences, Lanzhou, 730050, China
3 Laboratory of Nutrition and Functional Food, Jilin University, Changchun, 130062, China
4 The First Hospital of Jilin University, Jilin University, Changchun, 130021, China

† These authors contributed equally to this work.

* Authors to whom correspondence should be addressed; E-Mails: yulu225@yahoo.com.cn (L.Y.); wxp33@yahoo.com (X.-P.W.); Tel.: +86-431-87836713(L.Y.); +86-431-87836713 (X.-P.W.); Fax: +86-431-87836160 (L.Y.); +86-431-87836160 (X.-P.W.).

Received: 1 September 2010; in revised form: 2 October 2010 / Accepted: 25 October 2010 / Published: 29 October 2010

Abstract: The active multidrug efflux pump (EP) has been described as one of the mechanisms involved in the natural drug resistance of bacteria, such as mycobacteria. As a result, the development of efflux pumps inhibitors (EPIs) is an important topic. In this study, a checkerboard synergy assay indicated that farnesol both decreased the minimum inhibitory concentration (MIC) of ethidium bromide (EtBr) 8-fold against Mycobacterium smegmatis (M. smegmatis) mc²155 ATCC 700084 when incorporated at a concentration of 32 µg/mL (FICI = 0.625) and decreased MIC 4-fold at 16 µg/mL (FICI = 0.375). Farnesol also showed synergism when combined with rifampicin. A real-time 96-well plate fluorometric method was used to assess the ability of farnesol to inhibit EPs in comparison with four positive EPIs: chlorpromazine, reserpine, verapamil, and carbonyl cyanide m-chlorophenylhydrazone (CCCP). Farnesol significantly enhanced the accumulation of
EtBr and decreased the efflux of EtBr in *M. smegmatis*; these results suggest that farnesol acts as an inhibitor of mycobacterial efflux pumps.

**Keywords:** farnesol; inhibitor; efflux pump; *Mycobacterium smegmatis*

**Introduction**

Some mycobacteria are pathogens that can cause significant morbidity and mortality; among these, *Mycobacterium tuberculosis* (*M. tuberculosis*) is one of the oldest and most common causes of infection and death in the World, *Mycobacterium avium* (*M. avium*) often causes blood infection in AIDS patients, and *Mycobacterium smegmatis* (*M. smegmatis*) is also an opportunistic pathogen [1]. The 13th annual tuberculosis (TB) report from the World Health Organization (WHO; published on World TB Day, March 24, 2009) revealed that there were an estimated 9.27 million new cases of tuberculosis worldwide in 2007 [2]. With the emergence of mycobacteria expressing multidrug resistance (MDR), there is an urgent need for new antituberculosis drugs to treat TB [3].

Membrane-based efflux pump (EP) systems play an important role in bacterial pathogenicity and antimicrobial resistance in bacteria. Recent reports have shown that efflux pumps (EPs) can decrease intracellular drug concentrations used in a clinical setting and that changes in the expression of EPs can rapidly result in antibiotic resistance [4] by preventing the compounds from reaching their intended targets [5,6]. Effective bacterial EP inhibitors (EPIs) should decrease the intrinsic resistance of bacteria to antibiotics, reverse acquired resistance and reduce the frequency of the emergence of newly resistant mutant strains [7]. To our knowledge, few EPIs for mycobacteria have been identified so far [8]. Even though several experimental compounds, such as reserpine, chlorpromazine, verapamil and carbonyl cyanide m-chlorophenylhydrazone (CCCP), have been shown to have EPI effects against mycobacteria both *in vitro* and *ex vivo* [8,9], these compounds have not yet fulfilled certain requirements of clinical relevancy (*i.e.*, serum concentration, toxicity, immunosuppression, and stability and solubility concerns) in human or veterinary medicine [10,11]. Therefore, it is important to explore new EPIs for mycobacteria.

Recent reports have shown that the 15-carbon isoprenoid component farnesol (Figure 1), a natural plant metabolite, can intensify the effect of antimicrobial agents on *Staphylococcus aureus* (*S. aureus*) and *Escherichia coli* (*E. coli*) [12,13]. These studies demonstrated that farnesol inhibits oxidation–reduction reactions and also increases the susceptibility of *S. aureus* to gentamicin; because gentamicin requires ATP-dependent transport to enter the cells, this result suggests that membrane integrity is disrupted by farnesol [14].

![Chemical structure of farnesol.](image)
Membrane damage would also facilitate the penetration of antibiotics, such as macrolides and quinolones [13]. Farnesol is likely to be potent, providing effective K⁺ leakage from the cytoplasm and causing less toxicity in humans [15]. These interesting results led us to investigate whether farnesol exhibits EPI activity in mycobacteria.

Ethidium bromide (EtBr) is a biocompatible molecule that neither affects cell viability nor perturbs cellular functions under defined and controlled conditions; it is also a well-known substrate of many EPs in various multidrug-resistant microorganisms, including *S. aureus* and mycobacteria [10,16,17]. *Mycobacterium smegmatis* (*M. smegmatis*) is nonpathogenic, requiring less stringent containment facilities, and it grows at a relatively high rate in many defined and nutrient-restricted media [18]. Therefore, it is advantageous to use EtBr and *M. smegmatis* collaboratively to study EPI activity. In this study, we used a real-time 96-well plate fluorometric method that has recently been described [9,19], employing a modification in order to evaluate the inhibiting effects of farnesol on the *M. smegmatis* mc²155 drug efflux system.

**Results**

**MIC results**

MIC values of all the compounds tested are listed in Table 1. The compound farnesol showed antimycobacterial activity at a MIC of 64 µg/mL. The MICs of EtBr, chlorpromazine, reserpine, verapamil and CCCP for *M. smegmatis* mc²155 were 8, 32, 256, 300, and 25 µg/mL, respectively; these findings are similar to previous results [8,9]. These data indicate that the antimycobacterial activity of farnesol is better than that of the positive control EPIs reserpine and verapamil and worse than that of chlorpromazine and CCCP. The MICs of these compounds for *M. smegmatis* mc²155 were also later used as a reference for determining the EPI concentrations for the EP inhibition assay. The MIC of rifampicin is 64 µg/mL against *M. smegmatis* mc²155.

| Compound     | MIC (µg/mL) | Concentration as modulator (µg/mL) | Modulation factor (EtBr) | FICI  |
|--------------|-------------|------------------------------------|--------------------------|-------|
| Farnesol     | 64          | 8                                  | 2                        | 0.625 |
|              |             | 16                                 | 8                        | 0.375 |
|              |             | 32                                 | 8                        | 0.625 |
| Chlorpromazine| 32          | 8                                  | 1                        | 1.25  |
|              |             | 16                                 | 4                        | 0.75  |
| Reserpine    | 256         | 32                                 | 2                        | 0.625 |
|              |             | 64                                 | 4                        | 0.5   |
| Verapamil    | 300         | 32                                 | 1                        | 1.107 |
|              |             | 64                                 | 2                        | 0.713 |
| CCCP         | 25          | 16                                 | 2                        | 1.14  |

MIC of EtBr = 8 µg/mL; Modulation factor = MIC (EtBr)/MIC (EtBr + modulator).
Checkerboard synergy assay results

In this experiment, the checkerboard synergy assay was employed to evaluate both the synergistic interactions of farnesol, reserpine, verapamil, chlorpromazine and CCCP with EtBr and the modulation of EPIs on the MIC of EtBr against *M. smegmatis* mc²155 ATCC 700084. The results are listed in Table 1. The FICI between farnesol at 16 µg/mL and EtBr at 1 µg/mL was 0.375, indicating a good synergism, whereas the FICIs between chlorpromazine, verapamil, CCCP and EtBr all showed indifferent interactions (FICI = >0.5~2), and the combination of reserpine and EtBr showed a weak synergism (FICI = 0.5). In addition, the FICI between farnesol at 16 µg/mL and rifampicin at 8 µg/mL was 0.375. These results suggest that farnesol may be a potential inhibitor of efflux pump in *M. smegmatis*.

EtBr efflux inhibition

In an EtBr accumulation assay, we compared the levels of EtBr accumulation in *M. smegmatis* cells treated by reserpine, chlorpromazine, verapamil, CCCP and farnesol within 45 minutes (see Figure 2). The level of EtBr accumulation in the control group (no EPI treatment) was the lowest. However, with the addition of the positive control EPIs or farnesol, the level of EtBr accumulation in the experimental groups increased significantly. The verapamil group had the highest level of EtBr accumulation among the groups; the CCCP group showed a higher level of EtBr accumulation than the reserpine group, and the chlorpromazine group showed the lowest level of accumulation. Compared to these EPI-treated groups, the level of EtBr accumulation induced by farnesol treatment was higher than the verapamil treatment.

**Figure 2.** Effect of EPIs on the accumulation of EtBr in *M. smegmatis* mc²155 cells. Concentrations of reserpine, chlorpromazine, verapamil, CCCP and farnesol are at half their MICs (See also Table 1).

The results of the EtBr efflux assay of *M. smegmatis* cells within 45 minutes of treatment by reserpine, chlorpromazine, verapamil, CCCP and farnesol are shown in Figure 3. According to the results in Figure 3(a), each known EPI tested showed efflux inhibition in *M. smegmatis* mc²155 cells.
Verapamil had the strongest ability to inhibit the activity of the efflux pump in *M. smegmatis* mc²155 cells relative to the other three positive EPIs. CCCP exhibited a stronger ability to inhibit the activity of the efflux pump in *M. smegmatis* mc²155 cells relative to reserpine. Though the chlorpromazine group showed the weakest effect, it also showed efflux inhibition activity in *M. smegmatis* mc²155 cells. Compared with the groups that were treated with EPIs, the efflux inhibition ability of farnesol was higher than CCCP but lower than verapamil. Mean results were expressed as the percentage inhibition of total efflux observed for *M. smegmatis* mc²155 cells in the absence of inhibitors in Figure 3 (b).

**Figure 3.** Effect of EPIs on the efflux of EtBr in *M. smegmatis* mc²155 cells (a) and the percentage inhibition of efflux pump by EPIs (b). The assay was conducted at 25 °C with glucose, after loading the mycobacteria with EtBr at 4 µg/mL in the presence of verapamil at half its MIC. Concentrations of reserpine, chlorpromazine, verapamil, CCCP and farnesol are at half of their MICs (Table 1). The horizontal line indicates 50% efflux inhibition in Figure 3 (b).
Figure 4 showed that a higher concentration of farnesol resulted in a stronger EtBr efflux inhibitory effect in *M. smegmatis* mc²155 cells, indicating that farnesol acted in a concentration-dependent manner during the period of the assay.

**Figure 4.** Effect of farnesol and verapamil on the accumulation (a) and efflux (b) of EtBr from *M. smegmatis* mc²155 cells in different concentrations.

**Discussion**

Drug resistance in mycobacteria (particular multidrug-resistant strains of *M. tuberculosis*) is increasing yearly, a phenomenon that seriously threatens the ability of medicine to control TB. It is difficult to reverse this situation without ensuring that all patients are diagnosed rapidly and treated effectively so that resistant strains are not produced and transmitted in the community [20]. It has been established that the expression of EPs is one of the mechanisms involved in the natural drug resistance of mycobacteria [5]. There are five families of bacterial drug EPs [21]. Two of these are large superfamilies of ancient origin are as follows: the ATP-binding cassette (ABC) superfamily and the major facilitator superfamily (MFS); the other three are smaller families that have developed more recently: the small multidrug resistance (SMR) family, the resistance-nodulation-cell division (RND) family, and the multidrug and toxic compounds extrusion (MATE) family. These EPs can transport drugs through the bacterial envelope and limit the intracellular accumulation of toxic compounds, such as antibiotics, antimicrobial peptides, metals and detergents [11]. Therefore, there is an urgent need for novel drugs with new modes of action, such as EPIs, to prevent the rise of MDR bacteria [16]. There are currently no EPI/antimicrobial drug combinations on the market, although both academic
institutions and the pharmaceutical industry are continually conducting research to identify potential 
EPIs [22]. Identifying EPIs from natural sources is an alternative approach.

As mentioned above, the isoprenoid component farnesol has been found to enhance the effects of 
antimicrobial agents on *S. aureus* and *E. coli* [12,13]. In this experiment, two different assays were 
performed to identify whether farnesol has the potential to act as an efflux inhibitor on *M. smegmatis*
mc²155 possessing an EP; these assays included a checkerboard synergy assay on antimycobacterial 
synergism and a fluorometric method on a real-time basis. Checkerboard techniques have been widely 
used to evaluate the activity of antimicrobial combinations [23,24]. The real-time 96-well plate 
fluorometric method requires relatively small volumes of the EPIs, making it especially advantageous 
for testing rare or expensive compounds [9,19,25]. In the fluorometric method, fluorochrome EtBr has 
a low fluorescence signal outside the bacterial cell that increases once inside the cell in a 
concentration-dependent manner and is widely recognized as the best candidate for monitoring EP 
activity [9]. In the present experiments, referred to as Rodrigues *et al*. [9], four well-known EPIs 
(reserpine, chlorpromazine, verapamil and CCCP) were used as reference substances to evaluate the 
extent of possible efflux inhibition in the fast-growing mycobacterial strain *M. smegmatis* mc²155.

According to the results of the checkerboard synergy assay, farnesol decreased the MIC of EtBr 8-fold 
at 32 µg/mL, indicating that farnesol was effective in blocking EtBr efflux in *M. smegmatis* and that it 
may be a potential inhibitor of EtBr efflux in *M. smegmatis*. Couto *et al.* demonstrated that a reduction 
in the MICs to at least a quarter of their original values in the presence of the EPI was considered to be 
indicative of efflux activity [26]. The FICI between farnesol at 16 µg/mL and EtBr at 1 µg/mL was 
0.375, showing a good synergism; in contrast, the positive control EPIs all showed indifference, except 
for the combination of reserpine and EtBr, which showed a weak synergy (FICI = 0.5). These results 
indicate that farnesol is effective in blocking EtBr efflux like the reference EPIs used here. Farnesol 
not only increased the intrinsic susceptibility of *M. smegmatis* to EtBr but also showed exhibited a 
higher level of antimycobacterial activity and a better effect on the MIC of EtBr, compared with the 
reference EPIs. From the fluorometric method, farnesol significantly enhanced the accumulation of 
EtBr and the inhibition of efflux from cells preloaded with EtBr; this result suggested that farnesol acts 
as an EPI in mycobacterium. Noteworthily, in our study, farnesol also showed synergistic effect when 
combined with rifampicin in *M. smegmatis* mc²155, this furtherly confirmed that farnesol has efflux 
pump inhibition activity in mycobacterium.

Bacterial resistance to antibiotics typically involves drug inactivation or modification, target 
alteration, or a decrease in drug accumulation associated with a decrease in permeability and/or an 
increase in efflux [27]. It is now generally understood that EPs are becoming an important mechanism 
of resistance, both alone and in synergy with changes in the permeability of the outer membrane [28]. 
Several compounds have been reported to not only have EP inhibition ability but also affect membrane 
permeability, leading to disruption of cytoplasmic membranes. For example, chlorpromazine has also 
been reported to bind to membranes, increasing their permeability [8,29]; chlorpromazine may affect 
the integrity of the cell wall of a *M. smegmatis* strain expressing Tap (a protein from *Mycobacterium fortuitum*), allowing tetracycline to enter cells and to accumulate in large amounts and rendering Tap 
activity inefficient [30]. Another NorA EPI in *S. aureus*, totarol (a phenolic diterpene), may disrupt the 
membrane phospholipids of bacteria, leading to a loss of membrane integrity [31]. Brehm-Stecher *et al.* 
[13] indicated that the sesquiterpenoid compound farnesol can enhance permeability as a result of
disruption of the cytoplasmic membrane [22]. Farnesol can disrupt the normal barrier function of the bacterial cell membrane, allowing the permeation into the cell of exogenous solutes such as EtBr and antibiotics [13]. The result of present study showed that farnesol has EP inhibition activity, including enhanced accumulation of EtBr and inhibition of efflux from cells preloaded with EtBr. Thus, similar to chlorpromazine and totarol, farnesol is an EPI, and it additionally affects membrane permeability through the disruption of cytoplasmic membranes.

In previous reports, farnesol has been shown to inhibit the proliferation of pancreatic cancer cells in vitro and in vivo [32], to affect the development of cariogenic biofilms by enhancing the cariostatic effectiveness of fluoride [33], to promote apoptosis and inhibit the growth of Candida albicans [34], and also to lower blood pressure in a hypertensive animal model [35]. Because farnesol and many other sesquiterpenoids are generally recognized as safe, these compounds may prove useful in combination with antimicrobials intended for use in foods or on food contact surfaces [13].

Experimental

Chemicals

Chlorpromazine, reserpine, verapamil, farnesol, rifampicin (Sigma-Aldrich), and carbonyl cyanide m-chlorophenylhydrazone (CCCP; Fluka) were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich, Steinheim, Germany). EtBr (Sigma-Aldrich) was dissolved in water. The components of the phosphate-buffered saline (PBS) were 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4. The chemical structure of farnesol is shown in Figure 1.

Strain and culture conditions

M. smegmatis mc²155 ATCC 700084 (LGC Promochem, Teddington, Middlesex, UK) was used throughout the study. Bacterial cells were grown at 37 °C in Middlebrook 7H9 broth or Middlebrook 7H11 agar medium (Difco Laboratories, Detroit, MI), both supplemented with 10% oleic acid–albumin–dextrose complex (OADC). These strains were suspended in PBS to prepare a standard inoculum which was used to determine the minimum inhibitory concentrations (MICs). To ensure a anvariable number of bacterial cells between experiments, the number of colony-forming units (cfu) in accord with aliquots of the inoculum was routinely calculated [9].

Determination of antibacterial susceptibility

MICs of EtBr, chlorpromazine, reserpine, verapamil, CCCP, rifampicin and farnesol were determined by the broth microdilution method adapted from previous studies and in accordance with the NCCLS guidelines [9,36]. Briefly, M. smegmatis mc²155 was grown in 7H9/OADC-supplemented medium at 37 °C to an optical density at 600 nm (OD₆₀₀) of 0.8. The bacterial cultures were diluted in PBS and the suspension turbidity was adjusted equivalent to a McFarland standard of 0.5. The adjusted bacterial suspension was diluted 100-fold to prepare the final inoculum used in the experiments, and 0.1 mL aliquots were added to each well of the 96-well plate. These wells already contained 0.1 mL of each agent at concentrations prepared from 2-fold serial dilutions in 7H9/OADC-supplemented medium. The plates were incubated at 37 °C after a period of time to measure the MIC results. Growth
in the agent-free control-well was the evidence of the end of the test period. The MIC was defined as the lowest concentration of compound that inhibited visible growth.

**Checkerboard synergy assay**

The activities of farnesol, in combination with EtBr, were evaluated in duplicate against *M. smegmatis* mc²155 by the checkerboard titration method in 96-well round-bottomed plates. Plates contained bacterial inocula (the same amount as was used in the above-mentioned drug susceptibility testing) and 2-fold serial dilutions of the compounds in total volumes of 200 mL of broth. The maximum and minimum concentrations of each diluted drug were at least a 4-fold increase of their MIC. Following seven days of incubation at 37 °C, the MICs of the drug combinations were read by visual inspection and the fractional inhibitory concentration index (FICI) for *M. smegmatis* mc²155 was calculated by the following equation [37]:

\[
\text{FICI} = \frac{C_{A_{comb}}}{\text{MIC}_{A_{alone}}} + \frac{C_{B_{comb}}}{\text{MIC}_{B_{alone}}}
\]

where MIC\(_{A_{alone}}\) and MIC\(_{B_{alone}}\) are the MIC values of drugs A and B when acting alone and C\(_{A_{comb}}\) and C\(_{B_{comb}}\) are concentrations of drugs A and B at the isoeffective combinations, respectively. The interpretation of the FICI was as follows: an FICI value of \(\leq 0.5\) represented synergy, an FICI value between 1 and 4 represented indifference, and an FICI value > 4 represented antagonism [38]. The same operation was conducted to evaluate the FICI between farnesol and rifampicin against *M. smegmatis* mc²155.

**Measurement of EtBr accumulation**

This assay was performed according to modification of the previous methods by Rodrigues *et al.* [9] and Coldham *et al.* [19]. *M. smegmatis* mc²155 were grown in 7H9/OADC-supplemented medium (10 mL) at 37 °C to an OD\(_{600}\) of 0.8. The culture was centrifuged at 13,000 rpm for 3 min, the supernatant was removed, the pellet was washed once and then re-suspended in PBS. After adjusting the OD to 0.4, glucose and EtBr (to yield a final concentration of 0.4% and 1 µg/mL, respectively) were added to one set of microtubes containing 1.0 mL of bacterial suspension. Aliquots of 0.095 mL were distributed to replica sets of 0.2 mL microtubes and 0.005 mL EPIs were added. Replica tubes that without any EPI served as controls. The fluorescence was measured in real-time using a Victor3 1420 multilabel counter (Wallac Oy., Turku, Finland) equipped with a plate heater set at 25 °C. The fluorescence at excitation and emission wavelengths of 530 nm (bandwidth 5.0 nm) and 600 nm (bandwidth 10.0 nm), respectively, was measured at 3-min intervals for 45 min. Each experiment was repeated three times.

**Measurement of EtBr efflux**

The effect of the agents on EtBr efflux activity was tested according to a modification of fluorescence techniques recently reported [9,19]. To ensure the maximum uptaking of *M. smegmatis* mc²155 cells with EtBr, conditions, as confirmed by cfu counting, were exhibited to lead to maximum accumulation of EtBr without causing any significant inhibition of growth. The assay was performed as follows: accumulation at 25 °C without glucose, the use of an EtBr concentration that caused a higher accumulation without compromising the cellular viability (4 µg/mL, corresponding to half the MIC) and the presence of verapamil at half its MIC (150 µg/mL, which was used to make sure that all
the *M. smegmatis* mc²155 cells can load up maximum EtBr). The EtBr-loaded cells were centrifuged at 13,000 rpm for 3 min and re-suspended in PBS containing 0.4% glucose but no EtBr. After adjusting the OD₆₀₀ to 0.4, aliquots of 0.095 mL were transferred to replicate 0.2-mL microtubes and 0.005-mL EPIs added. Replica tubes that without any EPI served as controls. EtBr efflux from the cells was monitored with a Victor3 1420 multilabel counter (Wallac Oy., Turku, Finland) equipped with a plate heater set at 25 °C. The fluorescence at excitation and emission wavelengths of 530 nm (bandwidth 5.0 nm) and 600 nm (bandwidth 10.0 nm), respectively, was measured at 3-min intervals for 45 min. Raw fluorescence values were analyzed using Excel (Microsoft) and subtraction of the appropriate control blanks. Each experiment was repeated three times.

**Conclusions**

In summary, we show that farnesol not only increased the intrinsic susceptibility of *M. smegmatis* to EtBr but also presented relatively good antimycobacterial activity compared with the reference EPIs; farnesol possesses an EP inhibition ability that enhanced the accumulation of EtBr and the inhibition of efflux from cells preloaded with EtBr in *M. smegmatis* mc²155. In future studies, we plan to evaluate the underlying molecular mechanism of farnesol as an inhibitor for mycobacterial EPs.

**Acknowledgements**

This work was supported by funding from Important National Science & Technology Specific Projects (2008ZX10301), the Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP) (No.200801831051), the Fund for Science & Technology Development of Jilin Province, China (No.200705233), and the Fundamental Research Funds for the Central Universities.

**Reference**

1. Han, X.Y.; Dé, I.; Jacobson, K.L. Rapidly growing mycobacteria: Clinical and microbiologic studies of 115 cases. *Am. J. Clin. Pathol.* 2007, 128, 612-621.
2. World Health Organization. *Global Tuberculosis Control: Epidemiology, strategy, financing*; WHO/HTM/TB: Geneva, Switzerland, 2009; p. 411.
3. Bloom, B.R.; Murray, C.J. Tuberculosis: Commentary on a reemergent killer. *Science* 1992, 257, 1055-1064.
4. German, N.; Kaatz, G.W.; Kerns, R.J. Synthesis and evaluation of PSSRI-based inhibitors of *Staphylococcus aureus* multidrug efflux pumps. *Bioorg. Med. Chem. Lett.* 2008, 18, 1368-1373.
5. De Rossi, E.; Aínsa, J.A.; Riccardi, G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. *FEMS Microbiol. Rev.* 2006, 30, 36-52.
6. Gupta, A.K.; Chauhan, D.S.; Srivastava, K.; Das, R.; Batra, S.; Mittal, M.; Goswami, P.; Singhal, N.; Sharma, V.D.; Venkatesan, K.; Hasnain, S.E.; Katoch, V.M. Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria. *J. Commun. Dis.* 2006, 38, 246-254.
7. Marquez, B. Bacterial efflux systems and efflux pumps inhibitors. *Biochimie* 2005, 87, 1137-1147.
8. Lechner, D.; Gibbons, S.; Bucar, F. Plant phenolic compounds as ethidium bromide efflux inhibitors in *Mycobacterium smegmatis*. *J. Antimicrob. Chemother.* 2008, 62, 345-348.

9. Rodrigues, L.; Wagner, D.; Viveiros, M.; Sampaio, D.; Couto, I.; Vavra, M.; Kern, W.V.; Amaral, L. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in *Mycobacterium avium* and *Mycobacterium smegmatis*. *J. Antimicrob. Chemother.* 2008, 61, 1076-1082.

10. Gibbons, S.; Oluwatuyi, O.; Kaatz, G.W. A novel inhibitor of multidrug efflux pumps in *Staphylococcus aureus*. *J. Antimicrob. Chemother.* 2003, 51, 13-17.

11. Piddock, L.J. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacterial. *Clin. Microbiol. Rev.* 2006, 19, 382-402.

12. Kuroda, M.; Nagasaki, S.; Ohta, T. Sesquiterpene farnesol inhibits recycling of the C55 lipid carrier of the murein monomer precursor contributing to increased susceptibility to beta-lactams in methicillin-resistant *Staphylococcus aureus*. *J. Antimicrob. Chemother.* 2007, 59, 425-432.

13. Brehm-Stecher, B.F.; Johnson, E.A. Sensitization of *Staphylococcus aureus* and *Escherichia coli* to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. *Antimicrob. Agents Chemother.* 2003, 47, 3357-3360.

14. Jabra-Rizk, M.A.; Meiller, T.F.; James, C.E. Shirtliff, M.E. Effect of farnesol on *Staphylococcus aureus* biofilm formation and antimicrobial susceptibility. *Antimicrob. Agents Chemother.* 2006, 50, 1463-1469.

15. Inoue, Y.; Shiraishi, A.; Hada, T.; Hirose, K.; Hamashima, H.; Shimada, J. The antibacterial effects of terpene alcohols on *Staphylococcus aureus* and their mode of action. *FEMS Microbiol. Lett.* 2004, 237, 325-331.

16. Oluwatuyi, M.; Kaatz, G.W.; Gibbons, S. Antibacterial and resistance modifying activity of *Rosmarinus officinalis*. *Phytochemistry* 2004, 65, 3249-3254.

17. Stavri, M.; Piddock, L.J.; Gibbons, S. Bacterial efflux pump inhibitors from natural sources. *J. Antimicrob. Chemother.* 2007, 59, 1247-1260.

18. Jacobs, W.R., Jr. *Mycobacterium Tuberculosis*: A Once Genetically Intractable Organism. In *Molecular Genetics of Mycobacteria*; Hatfull, G.F., Jacobs, W.R., Jr., Eds.; ASM Press: Washington, DC, USA, 2000; pp. 1-36.

19. Coldham, N.G.; Webber, M.; Woodward, M.J.; Piddock, L.J. A 96-well plate fluorescence assay for assessment of cellular permeability and active efflux in *Salmonella enterica* serovar Typhimurium and *Escherichia coli*. *J. Antimicrob. Chemother.* 2010, 65, 1655-1663.

20. Viveiros, M.; Leandro, C.; Amaral, L. Mycobacterial efflux pumps and chemotherapeutic implications. *Int. J. Antimicrob. Agents* 2003, 22, 274-278.

21. Li, X.Z.; Zhang, L.; Nikaido, H. Efflux pump-mediated intrinsic drug resistance in *Mycobacterium smegmatis*. *Antimicrob. Agents Chemother.* 2004, 48, 2415-2423.

22. Kuroda, M.; Nagasaki, S.; Ito, R.; Ohta, T. Sesquiterpene farnesol as a competitive inhibitor of lipase activity of *Staphylococcus aureus*. *FEMS Microbiol. Lett.* 2007, 273, 28-34.

23. Ge, F.; Zeng, F.; Liu, S.; Guo, N.; Ye, H.; Song, Y.; Fan, J.; Wu, X.; Wang, X.; Deng, X.; Jin, Q.; Yu, L. *In vitro* synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against *Mycobacterium tuberculosis*. *J. Med. Microbiol.* 2010, 59, 567-572.
24. Guo, N.; Wu, X.; Yu, L.; Liu, J.; Meng, R.; Jin, J.; Lu, H.; Wang, X.; Yan, S.; Deng, X. *In vitro* and *in vivo* interactions between fluconazole and allicin against clinical isolates of fluconazole-resistant *Candida albicans* determined by alternative methods. *FEMS Immunol. Med. Microbiol.* **2010**, *58*, 193-201.

25. Spengler, G.; Martins, A.; Schelz, Z.; Rodrigues, L.; Aagaard, L.; Martins, M.; Costa, S.S.; Couto, I.; Viveiros, M.; Fanning, S.; Kristiansen, J.E.; Molnar, J.; Amaral, L. Characterization of intrinsic efflux activity of *Enterococcus faecalis* ATCC29212 by a semi-automated ethidium bromide method. *In Vivo* **2009**, *23*, 81-87.

26. Couto, I.; Costa, S.S. Viveiros M, Martins M, Amaral L. Efflux-mediated response of *Staphylococcus aureus* exposed to ethidium bromide. *J. Antimicrob. Chemother.* **2008**, *62*, 504-513.

27. Li, X.Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria. *Drugs* **2004**, *64*, 38, 410-419.

28. Poole, K. Efflux-mediated multiresistance in Gram negative bacteria. *Clin. Microbiol. Infect.* **2004**, *10*, 12-26.

29. Crowle, A.J.; Douvas, G.S.; May, M.H. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. *Chemotherapy* **1992**, *38*, 410-419.

30. Ramón-García, S.; Martín, C.; Aínsa, J.A.; De Rossi, E. Characterization of tetracycline resistance mediated by the efflux pump Tap from *Mycobacterium fortuitum*. *J. Antimicrob. Chemother.* **2006**, *57*, 252-259.

31. Micol, V.; Mateo, C.R.; Shapiro, S.; Aranda, F.J.; Villalaín, J. Effects of (+)-totarol, a diterpenoid antibacterial agent, on phospholipid model membranes. *Biochim. Biophys. Acta* **2001**, *1511*, 281-290.

32. Ong, T.P.; Heidor, R.; de Conti, A.; Dagli, M.L.; Moreno, F.S. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. *Carcinogenesis* **2006**, *27*, 1194-1203.

33. Koo, H.; Schobel, B.; Scott-Anne, K.; Watson, G.; Bowen, W.H.; Cury, J.A.; Rosalen, P.L.; Park, Y.K. Apigenin and tt-farnesol with fluoride effects on *S. mutans* biofilms and dental caries. *J. Dent. Res.* **2005**, *84*, 1016-1020.

34. Shirtslliff, M.E.; Krom, B.P.; Meijering, R.A.; Peters, B.M.; Zhu, J.; Scheper, M.A.; Harris, M.L.; Jabra-Rizk, M.A. Farnesol-induced apoptosis in *Candida albicans*. *Antimicrob. Agents Chemother.* **2009**, *53*, 392-401.

35. Luft, U.C.; Bychkov, R.; Gollasch, M.; Gross, V.; Rouillet, J.B.; McCarron, D.A.; Ried, C.; Hofmann, F.; Yagil, Y.; Yagil, C.; Haller, H.; Luft, F.C. Farnesol blocks the L-type Ca$^{2+}$ channel by targeting the alpha 1C subunit. *Arterioscler. Thromb. Vasc. Biol.* **1999**, *19*, 959-966.

36. National Committee for Clinical Laboratory Standards. *Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A*; NCCLS: Wayne, PA, USA, 2003.

37. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. *Clin. Microbiol. Infect.* **2000**, *6*, 503-508.
38. Odds, F.C. Synergy, antagonism, and what the checkerboard puts between them. *J. Antimicrob. Chemother.* **2003**, *52*, 1.

*Sample Availability:* Samples of the compound farnesol is available from the authors.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).